复方伸筋胶囊联合非布司他对痛风患者高尿酸血症的疗效与安全性研究
Research on the Therapeutic Effects and Safety of Compound Shenjin Capsules with Febuxostat in Gout-Related Hyperuricemia

目的：观察非布司他联合复方伸筋胶囊对痛风伴高尿酸血症的影响。方法：将60例痛风伴高尿酸血症患者分为对照组(非布司他治疗组)和观察组(常规非布司他治疗联合复方伸筋胶囊组)，每组30例。治疗持续4周，观察两组患者治疗前后血尿酸(UA)、C反应蛋白及黄嘌呤氧化酶(XOD)水平的变化，同时监测肝肾功能及不良反应。结果：治疗4周后，观察组较对照组更显著降低血尿酸水平((370 ± 27.5) μmol/L vs. (412 ± 22.5) μmol/L, P < 0.05)、CRP水平((10.1 ± 1.8) mg/L vs. (13.2 ± 2.0) mg/L, P < 0.05)及黄嘌呤氧化酶活性(XOD) (9.1 ± 2.1 vs. 17.2 ± 1.9, P = 0.001)，且未见严重不良反应。结论：复方伸筋胶囊联合非布司他治疗能有效降低痛风患者的血尿酸水平，减轻炎症反应，并在肝肾功能安全性方面表现良好。
Objective: To observe the effects of febuxostat combined with Compound Shenjin Capsules on gout with hyperuricemia. Methods: Sixty patients with gout and hyperuricemia were divided into a control group (febuxostat treatment group) and an observation group (febuxostat combined with Compound Shenjin Capsules), with 30 patients in each group. The treatment lasted for 4 weeks. Changes in serum uric acid (UA), C-reactive protein (CRP), and xanthine oxidase (XOD) levels were observed before and after treatment in both groups. Liver and kidney function, as well as adverse reactions, were also monitored. Results: After 4 weeks of treatment, the observation group showed a significantly greater reduction in serum uric acid levels ((370 ± 27.5) μmol/L vs. (412 ± 22.5) μmol/L, P < 0.05), CRP levels ((10.1 ± 1.8) mg/L vs. (13.2 ± 2.0) mg/L, P < 0.05), and XOD activity (9.1 ± 2.1 vs. 17.2 ± 1.9, P = 0.001) compared to the control group. No serious adverse reactions were observed. Conclusion: Febuxostat combined with Compound Shenjin Capsules effectively reduces serum uric acid levels and inflammation in gout patients and demonstrates good safety in terms of liver and kidney function.